A first-in-class drug's journey to market

A leading cause of blindness, GA affects more than 5 million people worldwide and 1 million in the United States alone. This investigational targeted C3 therapy helps regulate excessive activation of the complement cascade within the immune system, a known contributor to the progression of many serious diseases. The implemented development plan for pegcetacoplan consisted of two global Phase III studies across 15 countries in over 200 sites worldwide, with an additional open-label extension study that was awarded later. The complexities of the trials required a contract research organization (CRO) partner with global reach, scalable solutions and excellent project and data management, which is why Apellis turned to Labcorp for support.